A phase II randomized, double-blind, placebo-controlled study to evaluate naldemedine for the treatment of opioid-induced constipation (OIC) in patients with cancer pain.
Narikazu Boku(Tokyo Medical University), Masaru Narabayashi(Japanese Foundation For Cancer Research), Katsunori Tauchi(Japanese Foundation For Cancer Research), M. Okuno(Aichi Cancer Center), Koji Oda(Tokyo Metropolitan University), Yasukazu Kawai(Fukui Prefectural Hospital), Yura Suzuki(Japanese Foundation For Cancer Research), Takaaki Yokota(Japanese Foundation For Cancer Research), Mitsuhiro Mizutani(Miwa Internal Medicine Clinic), Ken Nakata(Sakai Municipal Hospital), Hideo Nakazawa(Iwata City Hospital), Ryujiro Suzuki(Toyohashi Municipal Hospital), Hiroshi Kojima(Ibaraki Prefectural Central Hospital), Katsunori Shinozaki(Japanese Foundation For Cancer Research), Hiroaki Kikukawa(Kumamoto Medical Center), Nobuyuki Katakami(Takarazuka City Hospital), Shiro Fujita
Cited by 1
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
|International Journal of Clinical Oncology|2015|600
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579
Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience
|Journal of Hepato-Biliary-Pancreatic Surgery|2000|396